



Casey Hein BSDH, RDH, MBA


President, Casey Hein & Associates, LLC Hagerstown, Maryland

Assistant Professor, School of Dental Hygiene
Dr. Gerald Niznick College of Dentistry
Rady Faculty of Health Sciences
University of Manitoba, Winnipeg, Manitoba, Canada









"Health care is among the best endowed of all industries in the richness of its science base...yet, an enormous amount of that scientific knowledge remains unused."

- D.M. Benvick. Disseminating innovations in health care.

JAMA. 2003;289(15):1969-1975.

1

Dental-Medical Integration

Whether entry through medicine or dentistry, all disciplines share responsibility for patient outcomes

Medical-dental collaboration

Facilitates continuity of care

Decreases fragmented care

Better patient outcomes

Increases efficiency and eventually cost of care

Whether entry through medicine or dentistry, all disciplines share responsibility for patient outcomes

Medical-dental collaboration

Facilitates continuity of care

Decreases fragmented care

Better patient outcomes

Increases efficiency and eventually cost of care

Providing Primary Care Services in the Dental Setting is not a New Concept

| Service | Service

4

How can OHCPs contribute to the war on diabetes?

• Empower patients with diabetes to maintain good oral hygiene
• Help patients with diabetes understand how untreated, or unstable periodontitis may undermine attempts to sustain glycemic control
• Customize TX that addresses the unique needs of patients with diabetes

Screen patients for diabetes and prediabetes
Identify patients who have diabetes that is poorly controlled
Provide testing for hyperglycemia
Reinforce self care prescribed by patients' physicians
Collaborate with patients' treating physicians to potentiate optimal health outcomes

Screen patients for diabetes and prediabetes
Provide patients is poorly controlled

Primary

Diabetes Mellitus Awareness, Treatment, and Control in Adults ≥ 20 (NHANES 2013-2016)

Not treated but aware uncontrolled

Treated and uncontrolled

15.2%

Not treated and controlled

Treated and uncontrolled


Not treated and uncontrolled


Solve Solve How NORL KIRL MIN. All Rights Round


E. 201 Casey How NORL KIRL MIN. All Rights Round

8









12

15

10

Criteria for Testing for Type 2 Diabetes or Prediabetes in Asymptomatic Adults Association • Testing should be considered in overweight or obese (BMI ≥ 25 kg/m2 or ≥ 23 kg/m2 in Asian Americans) adults and who have one or more of the following risk factors: · First-degree relative with diabetes · High-risk race/ethnicity (e.g., African American, Latino, Native American, Asian American, Pacific Islander) · History of CVD • Hypertension (≥140/90 mmHg or on therapy for hypertension) • HDL cholesterol level <35 mg/dL (0.90 mmol/L) and/or a triglyceride level >250 mg/dL (2.82 mmol/L) Casey Her



American Diabetes Patients with A1c ≥ 5.7% (39 mmol/mol), IGT, or IFG on previous testing should be tested yearly · Women who were diagnosed with GDM should have lifelong testing at last every 3 years · If results are normal, testing should be repeated at a minimum of 3-year intervals, with consideration of more frequent testing depending upon initial results (e.g., those with prediabetes should be tested yearly) and risk status Casey Hei

13

14


Risk-Based Screening for Type 2 Diabetes and Prediabetes in Asymptomatic Children and Adolescents · Testing should be considered for individuals after the onset of puberty or after 10 years of age, whichever comes first and who are overweight (≥ 85% percentile) or obese (≥ 95% percentile), and who have one or more additional risk factors: · Maternal history of diabetes or GDM during the child's gestation · Family history of type 2 diabetes in first- or seconddegree relative Casey Hei 16



Diagnostic Criteria for Diabetes and Prediabetes HbA1c (%) rediabetes and typ 2 diabetes, fasting ≥ 126 mg/dL ≥ 200 mg/dL ≥ 6.5% olasma glucose, 2-h Diabetes plasma glucose, plasma glucose during 75-g oral 7.0 mmol/dL (11.1 mmol/dL) (48 mmol/mol) test and A1C are mg/dL (5.6-(7.8-11.0 (39-47 qually appropriate Prediabetes 6.9 mmol/L) mmol/L) mmol/mol) Casey Hei


18 17





19






21

20








22 23 24









25 26









28

A New Therapeutic Target: Periodontal Disease Remission/Control, with Reduced Periodontium ·Symptoms become less severe but not fully resolved · Significant decrease in inflammation Improvement in other clinical parameters Low disease activity may be • Modifying and predisposing factors an acceptable alternative therapeutic target in long not fully controlled standing disease · Stabilization of disease progression Casey He

Assessment of the Status/Stability

Operating St. a. Providend Plan in the same of the Status/Stability

Operating St. a. Providend Engine in the same of the Status of th

Who has the greatest risk for amplified systemic inflammation?

Charlie

Bob

Bob

Bob

Bob

Bob

Charlie

Company

33

36

31

32


35


Point-of-Care Glycemic Control Testing

**Cary Heise State S









39

42

37 38

CDT Code: D0412: Blood Glucose Level
Test-in-Office using a Glucometer (POCT)

• Effective January 1, 2019

• Provides immediate findings of a patient's blood glucose level at time of sample collection

• Added to plans that cover D0411

Hypogycemia 2 70 myld

Likely Acceptable 80 – 180 myld

**Carry Hein

**County Hein

Performing a Finger
Stick Procedure

1. Select finger, massage
2. Clean and dry site
3. Using a lancet, puncture skin
• 30-gauge lancet will suffice (for most people); 25 - 28 for thicker skin; 32 or 33 for very thin skin

4. Wipe away the first blood before collecting the sample without "milking the finger"

5. Place the sample into the analyzing device

6. Read the result; 5 minutes for PTS Diagnostics' A1c Now

41

Patient Candidates for Point-of-Care
Glucose Testing

Gingivitis or periodontitis
Obese or overweight
Sedentary lifestyle
Family HX of diabetes
Poor response to treatment
Delayed wound healing
Symptoms of diabetes
Immunocompromised
High risk ethnic background (e.g., African American, Latino, Native American, Asian American, Pacific Islander)

40

The Importance of Monitoring HbA1c in Patients who have Diabetes

• For patients with a history of well-controlled diabetes, increased blood sugar levels may signal increased risk for periodontal deterioration

• Patients with no history of periodontal disease

• Patients with no history of periodontal disease

• Patients in periodontal maintenance

• New patients

• Patients with pre-diabetes

43

HbA1c results may guide periodontal treatment plans customized to meet the needs of the patient with diabetes:

 TX with adjunctive therapies: hydrogen peroxide trays, site specific antimicrobials, host modulatory therapy (SDD)
 Periodontal surgery: potential for impaired healing
 Orthodontia
 Cosmetic dentistry or complex full mouth restoration
 Helps define re-care intervals

 CONClarg New MONTA AN Reple Record

CONClarg New MONTA AN Reple Record

What do we do with a Positive Test Result?


Inform patient
Recommend following through with physician for definitive DX
Patient release of record
Referrals must be documented and tracked
How might results influence current and future TX plans?
Does patient's dental insurance provide coverage for additional prophylaxis?

44 45









4.0


46

47

48








49 50

43

52

Mini-Messages for Passive Patient Education

When the condition of the con



Ask your patients when they were last tested for HbA1c; correlate with oral health status
Learn about point-of- care testing for hyper/hypo-glycemia
Stay the course and let me know how you do.

www.caseyhein.com

THANK YOU!

Casey Hen ISONL RISK, MIRA, All Righe Bennel

C 200 Casey Hen ISONL RISK, MIRA, All Righe Bennel

53 54